<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095571</url>
  </required_header>
  <id_info>
    <org_study_id>266376</org_study_id>
    <nct_id>NCT05095571</nct_id>
  </id_info>
  <brief_title>A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study</brief_title>
  <official_title>A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study. Extension Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elysium Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous&#xD;
      system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there&#xD;
      is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK per year.&#xD;
&#xD;
      Research i.a. from the investigators department has shown that increased activity in histone&#xD;
      deacetylation enzymes (sirtuins) together with increased access to NAD can delay disease&#xD;
      progression. Nicotinamide riboside (NR) can increase cells' access to NAD and Pterostilben&#xD;
      will stimulate sirtuins.&#xD;
&#xD;
      The investigators want to study whether combination therapy with NR and Pterostilben can&#xD;
      inhibit neurodegeneration in ALS and thereby delay disease development, increase survival and&#xD;
      improve quality of life in ALS.&#xD;
&#xD;
      In the NO-ALS extension study the investigators will follow the patients who completed the&#xD;
      original NO-ALS study. Objectives are to evaluate adverse events and give patients&#xD;
      possibility of compassionate use, and secondarily to see if EH301 will decrease progression&#xD;
      of motor symptoms and loss of vital capacity, and increase survival time in patients with&#xD;
      ALS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a multicenter open label study as a follow up of the NO-ALS trial. Newly diagnosed ALS cases were included in the study arm 1. Earlier ALS cases were included in study arm 2 to allow patients with earlier ALS to participate in the study as the treatment options outside the study were limited. The NO-ALS study will be stopped when we reach 180 patients in the group with newly diagnosed ALS cases (arm 1). This is the follow up study for pasients completing 1 year follow up in the NO-ALS study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through study completion, 1 year</time_frame>
    <description>Studies of adverse events including changes in lab parameters induced by high dose oral NR/pterostilbene.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease progression as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>Determined after 12 months of follow-up.</time_frame>
    <description>ALSFRS-R is a validated rating instrument for monitoring the progression of disability in patients with ALS. The minimum score is 0 and the maximum score is 48, the higher score the more function is retained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital capacity</measure>
    <time_frame>Determined after 12 months of follow-up.</time_frame>
    <description>Vital capacity measured by spirometry.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Determined after 12 months of follow-up.</time_frame>
    <description>Defined as how many are alive or not requiring continuous respiratory ventilation life support.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>NO-ALS Extension Study High Dose EH301</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EH301 (Nicotinamide Riboside/Pterostilbene)</intervention_name>
    <description>For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.</description>
    <arm_group_label>NO-ALS Extension Study High Dose EH301</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who fulfilled the criteria for the NO-ALS study and have completed the study&#xD;
             will be proposed inclusion in the NO-ALS extension study protocol. Patients from both&#xD;
             arm 1 and arm 2 in the NO-ALS study will be allowed inclusion in the prolongation&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals will be excluded if any of the following exclusion criteria apply:&#xD;
&#xD;
          -  Dementia, FTD or other neurodegenerative disorder interfereing with compliance.&#xD;
&#xD;
          -  Metabolic, neoplastic, or other physically or mentally debilitating disorder.&#xD;
&#xD;
          -  Patients who become tracheostomized as part of the treatment of ALS.&#xD;
&#xD;
          -  Patients with short expected survival at the discretion of the investigator. Such&#xD;
             cases cannot be expected to follow protocol procedures.&#xD;
&#xD;
          -  Use of Vit B3 or blue berry extracts outside the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole-Bjørn Tysnes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ole-Bjørn Tysnes</last_name>
    <phone>+4755975063</phone>
    <email>obty@haukeland.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole-Bjørn Tysnes</last_name>
      <phone>+4755975063/+4790686700</phone>
      <email>obty@haukeland.no</email>
    </contact>
    <investigator>
      <last_name>Ole-Bjørn Tysnes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset HF</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Espen Benjaminsen</last_name>
      <phone>+4748103893</phone>
      <email>Espen.Benjaminsen@nordlandssykehuset.no</email>
    </contact>
    <investigator>
      <last_name>Espen Benjaminsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Kristine Bjørnå</last_name>
      <phone>+4741339297</phone>
      <email>Ingrid.Kristine.Bjorna@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Ingrid Kristine Bjørnå</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde HF</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristin Lif Breivik</last_name>
      <phone>+4793630457</phone>
      <email>kristin.lif.breivik@helse-forde.no</email>
    </contact>
    <investigator>
      <last_name>Kristin Lif Breivik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Fonna HF</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ineke HogenEsch</last_name>
      <phone>+4752732590</phone>
      <email>ineke.hogenesch@helse-fonna.no</email>
    </contact>
    <investigator>
      <last_name>Ineke HogenEsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sørlandet sykehus</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Unn Ljøstad</last_name>
      <phone>+4741208824</phone>
      <email>unn.ljostad@sshf.no</email>
    </contact>
    <investigator>
      <last_name>Unn Ljøstad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet HF</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grethe Kleveland</last_name>
      <phone>+4797157819</phone>
      <email>Grethe.Kleveland@sykehuset-innlandet.no</email>
    </contact>
    <investigator>
      <last_name>Grethe Kleveland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ola Nakken</last_name>
      <phone>+4797659796</phone>
      <email>ola.nakken@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ola Nakken</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Møre og Romsdal</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Åse Morsund</last_name>
      <phone>+4747756360</phone>
      <email>Ase.Hagen.Morsund@helse-mr.no</email>
    </contact>
    <investigator>
      <last_name>Åse Morsund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Nord-Trøndelag HF</name>
      <address>
        <city>Namsos</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Devik</last_name>
      <phone>+4798833255</phone>
      <email>Kristina.Devik@helse-nordtrondelag.no</email>
    </contact>
    <investigator>
      <last_name>Kristina Devik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo Univerity Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelina Maniaol</last_name>
      <phone>+4797674106</phone>
      <email>angman@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Angelina Maniaol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset Østfold HF</name>
      <address>
        <city>Sarpsborg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erika Hallerstig</last_name>
      <phone>+4798455652</phone>
      <email>erika.carina.hallerstig@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Erika Hallerstig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset i Telemark HF</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Berit Jøntvedt</last_name>
      <phone>+4747262912</phone>
      <email>joan@sthf.no</email>
    </contact>
    <investigator>
      <last_name>Anne Berit Jøntvedt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katrin Ruth Schlüter</last_name>
      <phone>+4745236149</phone>
      <email>katrin.schluter@sus.no</email>
    </contact>
    <investigator>
      <last_name>Katrin Ruth Schlüter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margitta Kampmann</last_name>
    </contact>
    <investigator>
      <last_name>Margitta Kampmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital HF</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helene Ballo Kvernmo</last_name>
      <phone>+4791167718</phone>
      <email>Helene.Ballo.Kvernmo@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Helene Ballo Kvernmo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset i Vestfold HF</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolai Johan Brun</last_name>
      <phone>+4793243780</phone>
      <email>nicolai.j.brun@siv.no</email>
    </contact>
    <investigator>
      <last_name>Nicolai Johan Brun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

